BioHarvest Sciences (NASDAQ:BHST – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01, Zacks reports. BioHarvest Sciences had a negative return on equity of 1,041.86% and a negative net margin of 36.33%.The business had revenue of $9.07 million for the quarter, compared to analysts’ expectations of $9.24 million.
Here are the key takeaways from BioHarvest Sciences’ conference call:
- Q4 revenue was $9.1M (+25% YoY) and full?year revenue was $34.5M (+37% YoY), with Q4 adjusted EBITDA of $0.5M, improved gross margins (~59%), and year?end cash of $23M, reflecting materially stronger profitability and liquidity.
- The VINIA direct?to?consumer business exceeded 85,000 active users, earned the #1 U.S. resveratrol brand position, and the new VINIA Blood Flow Hydration launch is showing strong early traction (15% of new?customer revenue and ~4.8–4.9 ratings), prompting a shift to digital marketing to reach younger cohorts.
- The CDMO unit hit a major technical milestone by completing stage one for a rare fragrance plant (first?ever stable cell culture), retains 20% ownership of resulting compositions, has four active third?party programs (including Tate & Lyle and Saffron Tech), and expects external CDMO revenue to rise toward $4–6M in 2026.
- Management is investing heavily in CDMO and manufacturing capabilities (AI, process engineering, elicitation center) and increasing marketing spend, which will make near?term results lumpy and raise operating expenses but is presented as a deliberate trade?off to accelerate growth in 2027–2028.
BioHarvest Sciences Trading Down 0.7%
Shares of BioHarvest Sciences stock opened at $4.31 on Thursday. The firm has a market cap of $84.56 million, a price-to-earnings ratio of -7.07 and a beta of 1.15. BioHarvest Sciences has a 52-week low of $4.10 and a 52-week high of $12.80. The company’s 50-day simple moving average is $4.59 and its 200-day simple moving average is $6.63. The company has a quick ratio of 1.02, a current ratio of 1.35 and a debt-to-equity ratio of 0.30.
Hedge Funds Weigh In On BioHarvest Sciences
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the stock. Roth Mkm began coverage on shares of BioHarvest Sciences in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Friday, March 27th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, BioHarvest Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $13.00.
Read Our Latest Research Report on BHST
About BioHarvest Sciences
BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.
The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.
Recommended Stories
Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
-DORA.png){kind=small}
